Biotech | January 07, 2022
Merck KGaA to acquire biopharma CDMO Exelead for $780 million
The transaction is expected to close in the first quarter of 2022
The transaction is expected to close in the first quarter of 2022
Acting as both a Dual Protease and TMPRSS2 Inhibitor, Pentarlandir is about to enter FDA Phase III trial¬
Biogen paid Ionis a US $ 60 million one-time upfront payment
Doxycycline Hyclate Delayed Release tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria
The first pilot study from India analyzing Covaxin-Covishield mixed doses
The virtual world makes it possible to visualize, test, understand and predict what cannot be seen, before a patient is treated
Upon completion of successful human trials and regulatory approval, the joint venture's goal is to start delivering the second-generation vaccine in 2022 as soon as is practically possible
Emergency Use Authorisation application request to be submitted following one month required by FDA EUA guidance
ASC10 is an oral direct-acting antiviral drug candidate targeting RNA dependent RNA polymerase (RdRp) to treat SARS-CoV-2 infection
The combination enhances Comar's customer value proposition by adding complementary closure and jar products and related precision mold-making expertise
Subscribe To Our Newsletter & Stay Updated
